Baruah Vishwa Jyoti, Paul Rasana, Gogoi Dhrubajyoti, Mazumder Nirmal, Chakraborty Subrata, Das Aparoopa, Mondal Tapan Kumar, Sarmah Bhaswati
Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam, India.
Department of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
J Biomol Struct Dyn. 2022 Apr;40(7):2893-2907. doi: 10.1080/07391102.2020.1844056. Epub 2020 Nov 12.
A multi-omics-based approach targeting the plant-based natural products from Thumbai (), an important yet untapped potential source of many therapeutic agents for myriads of immunological conditions and genetic disorders, was conceptualized to reconnoiter its potential biomedical application. A library of 79 compounds from this plant was created, out of which 9 compounds qualified the pharmacokinetics parameters. Reverse pharmacophore technique for target fishing of the screened compounds was executed through which renin receptor (ATP6AP2) and thymidylate kinase (DTYMK) were identified as potential targets. Network biology approaches were used to comprehend and validate the functional, biochemical and clinical relevance of the targets. The target-ligand interaction and subsequent stability parameters at molecular scale were investigated using multiple strategies including molecular modeling, pharmacophore approaches and molecular dynamics simulation. Herein, isololiolide and 4-hydroxy-2-methoxycinnamaldehyde were substantiated as the lead molecules exhibiting comparatively the best binding affinity against the two putative protein targets. These natural lead products from and the combinatorial effects may have plausible medical applications in a wide variety of neurodegenerative, genetic and developmental disorders. The lead molecules also exhibit promising alternative in diagnostics and therapeutics through immuno-modulation targeting natural killer T-cell function in transplantation-related pathogenesis, autoimmune and other immunological disorders.Communicated by Ramaswamy H. Sarma.
图姆贝(Thumbai)是众多免疫疾病和遗传疾病治疗药物的重要但尚未开发的潜在来源,基于多组学方法针对其植物源天然产物进行研究,以探索其潜在的生物医学应用。构建了该植物的79种化合物库,其中9种化合物符合药代动力学参数。通过反向药效团技术对筛选出的化合物进行靶点垂钓,确定肾素受体(ATP6AP2)和胸苷酸激酶(DTYMK)为潜在靶点。运用网络生物学方法来理解和验证这些靶点的功能、生化及临床相关性。使用包括分子建模、药效团方法和分子动力学模拟在内的多种策略,研究了分子水平上的靶点-配体相互作用及后续稳定性参数。在此,异胡薄荷醇内酯和4-羟基-2-甲氧基肉桂醛被确认为对两个假定蛋白质靶点表现出相对最佳结合亲和力的先导分子。这些来自图姆贝的天然先导产物及其组合效应可能在多种神经退行性、遗传和发育疾病中具有合理的医学应用。这些先导分子还通过免疫调节靶向移植相关发病机制、自身免疫和其他免疫疾病中的自然杀伤T细胞功能,在诊断和治疗方面展现出前景。由拉马斯瓦米·H·萨尔马(Ramaswamy H. Sarma)传达。